Genmab Announces Initiation of U.S. FDA Regulatory Submission for Label Expansion of Daratumumab in Combination with Lenalidomide and Dexamethasone in Front Line Multiple Myeloma
January 22, 2019 10:57 ET
|
Genmab A/S
Company Announcement First part of regulatory package submitted to the U.S. FDA for label expansion of daratumumab in combination with lenalidomide and dexamethasone for patients with newly...
Genmab Announces 2018 Net Sales Figures for DARZALEX® (Daratumumab)
January 22, 2019 06:44 ET
|
Genmab A/S
Company Announcement Net sales of DARZALEX in 2018 totaled USD 2,025 millionGenmab receives royalties on worldwide sales from Janssen Biotech, Inc. Copenhagen, Denmark; January 22, 2019 – Genmab...
Major Shareholder Announcement
January 17, 2019 13:37 ET
|
Genmab A/S
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; January 17, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 30 of the Danish...
Genmab Achieves USD 75 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen
January 08, 2019 12:34 ET
|
Genmab A/S
Company Announcement Genmab to receive milestone payment of USD 75 million in DARZALEX collaborationMilestone triggered by sales of DARZALEX reaching USD 2 billion in a calendar year Copenhagen,...
Genmab to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 03, 2019 08:48 ET
|
Genmab A/S
Media Release Copenhagen, Denmark, January 3, 2019 Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 37th Annual J.P....
Genmab Announces European Commission Approval of DARZALEX® (daratumumab) Split Dosing Regimen
December 20, 2018 05:26 ET
|
Genmab A/S
Media Release Split dosing regimen approved by European CommissionProvides healthcare professionals with option to split first DARZALEX infusion over two consecutive daysApproval supported by data...
Genmab Announces Submission of Supplemental New Drug Application for Daratumumab in Front Line Multiple Myeloma in Japan
December 13, 2018 20:58 ET
|
Genmab A/S
Company Announcement Supplemental new drug application submitted in Japan for daratumumab in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed...
Grant of Restricted Stock Units to Board Members, Management and Employees and Grant of Warrants to Management and Employees in Genmab
December 10, 2018 13:41 ET
|
Genmab A/S
Company Announcement Copenhagen, Denmark; December 10, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 80,380 restricted stock units to...
Genmab to Hold R&D Update and 2018 ASH Data Review Meeting
December 03, 2018 02:17 ET
|
Genmab A/S
Media Release Event to be held today in San Diego, CaliforniaIndependent experts to discuss data presented at the 2018 ASH Annual MeetingMeeting to be webcast live and archived on www.genmab.com ...
Genmab to Hold R&D Update and 2018 ASH Data Review Meeting
November 26, 2018 08:30 ET
|
Genmab A/S
Media Release Event to be held live in San Diego, CaliforniaIndependent experts to discuss data presented at the 2018 ASH Annual MeetingMeeting to be webcast live and archived on www.genmab.com ...